Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

and chronic inflammatory demyelinating polyneuropathy (CIDP). While Immunovant (NASDAQ:IMVT) lost ~14% in reaction to the ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

for chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after stabilization with intravenous immunoglobulin (IVIG) to prevent relapse of neuromuscular disability and ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug t ...

Ernesto Olvera, a Visalia resident, has been fighting a rare autoimmune disease known as chronic inflammatory demyelinating ...

Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART ...

who are anti-acetylcholine receptor antibody-positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The Vyvgart Hytrulo prefilled syringe is approved as a 20 ...

HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion to treat CIDP in Canada TORONTO, March 27, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased ...